AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023
Pivotal ALPHA Phase III trial results will show benefit of danicopan, Alexion's first-in-class Factor D inhibitor, in improving clinically significant extravascular haemolysis while allowing patients with PNH to remain on standard of care treatment.Calquence data will reinforce role as a preferred treatment option for chronic lymphocytic leukaemia and mantle cell lymphoma.Interim clinical data will show promise of AZD0486, a novel T-cell engager for patients with relapsed or refractory follicular lymphoma.AstraZeneca will present new clinical and real-world data in multiple